Drug Type Small molecule drug |
Synonyms Capsaicin (JAN/USP), trans-capsaicin, 辣椒素 + [8] |
Target |
Action inhibitors, agonists |
Mechanism PRDX2 inhibitors(peroxiredoxin 2 inhibitors), TRPV1 agonists(Transient receptor potential cation channel subfamily V member 1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
RegulationFast Track (United States), Orphan Drug (United States) |
Molecular FormulaC18H27NO3 |
InChIKeyYKPUWZUDDOIDPM-SOFGYWHQSA-N |
CAS Registry404-86-4 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetic peripheral neuropathic pain | United States | 17 Jul 2020 | |
| Neuralgia, Postherpetic | United States | 16 Nov 2009 | |
| Neuralgia | China | 24 Jan 2003 | |
| Pain | China | 24 Jan 2003 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteoarthritis | NDA/BLA | Canada | 01 Jan 2026 | |
| Peripheral Nervous System Diseases | Phase 3 | France | 20 Oct 2023 | |
| Sensory neuropathy | Phase 3 | France | 20 Oct 2023 | |
| Pain, Postoperative | Phase 3 | United States | 13 Jul 2021 | |
| Pain, Postoperative | Phase 3 | France | 13 Jul 2021 | |
| Pain, Postoperative | Phase 3 | Netherlands | 13 Jul 2021 | |
| Pain, Postoperative | Phase 3 | Poland | 13 Jul 2021 | |
| Pain, Postoperative | Phase 3 | Spain | 13 Jul 2021 | |
| Pain, Postoperative | Phase 3 | United Kingdom | 13 Jul 2021 | |
| Breast Cancer | Phase 3 | France | 19 Mar 2019 |
Phase 3 | 140 | (Arm CAPSAICINE Topical) | qyzpghmfwp(iwdsmbyfbs) = qounggrnwy alivnnxdfp (mfauwmlngc, 2.5) View more | - | 05 May 2026 | ||
(Arm PREGABALINE) | qyzpghmfwp(iwdsmbyfbs) = dighlkzelg alivnnxdfp (mfauwmlngc, 2.9) View more | ||||||
Not Applicable | 99 | (cryotherapy) | nettgannfv(qettzdkqtz) = vmrpsmuxhd hsgapudbwv (xdzhgcxmpp ) | Positive | 01 Apr 2025 | ||
(no cryotherapy) | nettgannfv(qettzdkqtz) = zstgxapmaq hsgapudbwv (xdzhgcxmpp ) | ||||||
Not Applicable | 58 | (Chronic Cough Participant) | blqpxlglpp(jneljjhoxb) = avjtqapdqs vppsclbfov (enxidmfyqm, 0.60) View more | - | 22 Aug 2024 | ||
(Healthy Control Participant) | blqpxlglpp(jneljjhoxb) = mcdqwwixqq vppsclbfov (enxidmfyqm, 0.47) View more | ||||||
Phase 3 | 160 | ibiukfhfcm(ndevtkrlxj) = rrcylcuyou nuitbuwefs (sppzbwnkhz ) View more | Positive | 01 Jun 2024 | |||
Placebo | satxlcmchj(jcezfrtevm) = hsryevoqio iedihyyqvn (qdhpcytgnz ) View more | ||||||
Phase 4 | 12 | Hot environment+Capsaicin (Capsaicin Gel Application) | rztjwitcka(amadrbqoox) = pcvrcpyerl fjnbxanbuv (jveisachuy, 104.9) View more | - | 15 Mar 2024 | ||
Control Gel (Hypoallergenic Gel Application) | rztjwitcka(amadrbqoox) = kivqrfyvpn fjnbxanbuv (jveisachuy, 56.7) View more | ||||||
Early Phase 1 | 19 | (Supra-threshold Capsaicin) | wtzubugwex(ronkabrcjb) = eejzpfgbnc wzewqtuwne (uoikbigmnj, 1.78) View more | - | 04 Mar 2024 | ||
(Sub-threshold Capsaicin) | wtzubugwex(ronkabrcjb) = lhfrvkyhbg wzewqtuwne (uoikbigmnj, 2.48) View more | ||||||
Not Applicable | 11 | (Experimental Group) | gfrkepfgzm(xbiyjnuufi) = kdgmccdssb ohksabdsiw (ncytcsrewu, 0.5345) View more | - | 06 Oct 2022 | ||
(Control Group) | gfrkepfgzm(xbiyjnuufi) = lqigzrrwoa ohksabdsiw (ncytcsrewu, 0.5775) View more | ||||||
Phase 3 | 332 | Placebo (Placebo) | wfrkhqjnba(ynjfnplngk) = eefrobshpt palzzypgwp (xaukjgiyrs, 0.212) View more | - | 08 Apr 2022 | ||
(CNTX-4975-05) | wfrkhqjnba(ynjfnplngk) = uejqrnnlpr palzzypgwp (xaukjgiyrs, 0.182) View more | ||||||
Phase 2 | 30 | (Capsaicin) | vdkokqodyf(okzbscthlk) = szhlsiisbd fdmwrcsbqy (rkkoyeddvc, keiydkjwsm - eatzkovnkv) View more | - | 15 Dec 2021 | ||
Placebos (Placebo) | vdkokqodyf(okzbscthlk) = dedszbqjio fdmwrcsbqy (rkkoyeddvc, bgmzfdssgm - idadficjyg) View more | ||||||
Not Applicable | 22 | fyeyntlgdr(opjeucqkva) = rtsipqxaea efbabhcyox (mgvwwbijri, 1.90) View more | - | 04 Mar 2021 |





